Our research in Immunology
Intended for healthcare professionals, scientific audiences and media.
Pursuing pathbreaking science in Immunology
Hear from our Board Chair and CEO, Giovanni Caforio, MD, about our commitment to elevating patient care to new standards to deliver what matters most – the promise of living a better life.
At Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and pulmonology. While there has been progress with medicines for immune-mediated diseases, people living with these conditions may not respond to available treatments. Many continue to endure chronic symptoms and disease progression that can take a toll on their daily life.
Our goal is to restore some of what immune-mediated diseases have taken away — empowering patients and their loved ones to take back their lives.
Immunology focus areas
Our scientific innovation
Bristol Myers Squibb is focused on delivering scientific innovation with the empathy and urgency needed to advance care for people living with immune-mediated diseases.
As we continuously build and expand our portfolio, our teams work to identify mechanisms that may reset and promote balance in the immune system, with the goal of achieving long-term remission and, ultimately, curative therapies.
Discover how Bristol Myers Squibb’s pioneering research with tyrosine kinase 2 (TYK2) is changing how scientists tackle the challenge of immune-mediated diseases.
Hear from Jonathan Sadeh, MD, MSc, senior vice president of Immunology Development at Bristol Myers Squibb, about how the company aims to build a robust immunology portfolio with pathbreaking science that addresses the unmet needs of people living with immune-mediated diseases.
Alyssa Johnsen, MD, PhD, vice president and head of Late Clinical Development, Immunology at Bristol Myers Squibb, shares her perspective on the great strides that have been made in the science of modulating the body's immune response to treat disease.
Meet our Immunology researchers
Every day, each of us works to improve outcomes for patients fighting serious immune-mediated diseases. We're creative thinkers motivated by the practical application of our work, and innovators unafraid to step into uncharted territory. Together, we're building a better future for each other and the patients who need us most.
Rheumatology
Over 20 years ago, Bristol Myers Squibb pioneered the science of modulating the body’s immune response to treat disease, beginning with the company’s research in rheumatoid arthritis (RA). Building on that foundation, we continue to pursue pathbreaking science across rheumatic diseases including RA, psoriatic arthritis, lupus and ankylosing spondylitis. Fueled by the possibility to help more patients, we are following the science to tailor therapies to individual needs, improve outcomes and expand treatment options.
Subhashish Banerjee, MD, vice president & disease area head, Rheumatology and Dermatology at Bristol Myers Squibb, shares how the company is leveraging a pathways-based approach to advance research and ultimately elevate care for patients in need of new treatment options in systemic lupus erythematosus (SLE), also known as lupus.
Gastroenterology
Bristol Myers Squibb is pursuing innovative research to potentially change the course of gastrointestinal immune-mediated diseases, including inflammatory bowel disease (IBD) (which includes ulcerative colitis and Crohn's disease) and eosinophilic esophagitis (EoE). Our scientific innovations have the potential to provide relief and remission to people living with these conditions.
Dermatology
Through Bristol Myers Squibb’s pioneering exploration of immune pathways implicated in dermatologic conditions, our discovery team’s research is leading to the potential for safe, effective, category-defining new therapies that may address the pressing treatment gaps that continue to exist for people living with these conditions. With a highly focused pipeline, we are pursuing novel treatments for psoriasis and atopic dermatitis and exploring a broad range of serious dermatologic conditions in our early research.
Pulmonology
Bristol Myers Squibb is committed to applying expertise regarding the role of fibrosis in the development of several immune-mediated diseases to advance new treatments that go beyond symptom relief and address the underlying causes of disease.
Hear Bruce Ellsworth, PhD, scientific executive director, Medicinal Chemistry, and Aryeh Fischer, MD, Lung Fibrosis clinical development lead, discuss how Bristol Myers Squibb is leveraging its deep expertise in medicinal chemistry and disease biology to research potential treatments for pulmonary fibrosis.